Exhibition Recap | Hycells Biotechnology Launches Multiple New Products at IBI EXPO 2023
Release Date:
2023-07-21 13:26
Innovative biopharmaceuticals have become a fiercely contested frontier in the biopharmaceutical industry, and a comprehensive, mature supply chain is indispensable for the sector’s development. With global supply chains still vulnerable, domestic substitution of CDMO services and supply-chain components has emerged as a new perspective on translating research outcomes into commercial value for many companies in this field. Against this pharmaceutical landscape, the IBI EXPO 2023 International Conference on Innovative Biopharmaceuticals was established to meet the growing demand, and it will be held at July 13–15 at the Shanghai International Convention and Exhibition Center for Multinational Procurement The event was held in grand style. As a pioneer in domestic substitution, Hycells Biotechnology was also invited to attend the conference.
The photo shows leaders—including Zhu Rong, Deputy Director of the Biopharmaceutical Industry Division of the Shanghai Municipal Commission of Economy and Informatization; Jin Yulan, President of the Shanghai Pharmaceutical Quality Association; and He Wenqing, Executive Deputy Secretary-General of the Shanghai Biopharmaceutical Industry Association—cutting the ribbon to inaugurate the conference.
During the exhibition, a steady stream of customers and industry peers visited the Hycells Bio booth for discussions and exchanges. Hycells Bio is using this exhibition as its inaugural platform, Major Launch of Several New Company Products , comprehensively showcasing Hycells’s corporate and brand image to enable more people to get up close with the company and gain an in-depth understanding of it.
The process of bringing a new product or service from concept to reality—so that it truly benefits customers, empowers pharmaceutical R&D companies, and fosters indispensable collaboration with clients—tests our Core technological strength This rigorously tests the professional expertise and service quality of every team member. Hycells Bio continuously refines its quality management system and consistently upgrades and optimizes its technical service platform. Upholding a corporate culture and attitude of innovation, openness, and inclusiveness, the company leverages clinical needs and industry pain points to drive continuous product and service innovation, delivering truly valuable, differentiated offerings to its clients.
The photo shows industry peers exchanging ideas and discussing at the exhibition.
At the exhibition, Hycells Bio’s anniversary celebration and gratitude giveaway drew considerable attention from visitors. Surprise prizes—including Amazon Kindle e-readers, Tmall Genie smart speakers, elegant umbrellas, and custom notebooks—were awarded through on-site lucky draws and distributed immediately, creating a lively and enthusiastic atmosphere that brought the event to a thrilling climax.
The photo shows the on-site lucky draw for the anniversary gratitude event at Heyou.
This exhibition is another major event for the innovative drug R&D industry and a rewarding journey for Hycells Biotechnology. We will continue to uphold Based on talent, Quality First, Innovation as the Foundation Its core values are rooted in technological innovation, continuously enhancing the quality of clinical bio-sample collection, preparation, and application, setting new industry standards for domestic substitution, and providing a solid foundation for the development and global advancement of China’s innovative drugs.
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board